Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial.
2015 ◽
Vol 33
(15_suppl)
◽
pp. 5518-5518
◽
Keyword(s):
Phase I
◽